What Are the Research Highlights of Periprosthetic Joint Infections From the 100 Most Cited Studies? Authors: Marcos R Gonzalez, Jose I Acosta, Joshua Davis, Felipe Larios, Adam S Olsen, Antonia F Chen Published: 2024 ABSTRACT AbstractBackgroundPeriprosthetic joint infections (PJIs) are a serious complication after total joint arthroplasty. Our study aimed to analyze the characteristics and research highlights of the top 100 most cited studies on PJI from an orthopaedic standpoint. Moreover, we sought to assess whether there has been a change in the level of evidence (LOE) throughout time.MethodsWe conducted a search of the PubMed, Embase, and Web of Science databases to identify the top 100 studies primarily focusing on PJI. Study characteristics assessed included publication year, LOE, journal of publication, and type of study. Research highlights of the included studies were classified into 6 sections. Linear regression was employed to assess correlation between LOE and publication year.ResultsThe aggregated citation count of all studies was 19,558 and the median citation number was 129.5. While cohort studies were the most prevalent, articles focusing on analysis of costs associated with PJI care or PJI definition garnered the highest yearly citation counts. The bulk of included studies were concentrated in 3 orthopaedic journals and published in the 2010s. The majority of studies had a LOE II (30%) or III (34%). On regression analysis, LOE was not correlated with publication year (Pearson’s r = 0.013, P = .61).ConclusionsThe most cited PJI articles assessed the definition of PJI and PJI cost. Despite growing interest in PJI, the majority of studies had LOE II or III, highlighting the difficulty of conducting prospective randomized controlled trials in PJI patients.Level of evidenceIV.Keywords: Periprosthetic joint infection, Prosthetic joint infection, Total knee arthroplasty, Total hip arthroplasty Introduction Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are elective surgical procedures with excellent long-term results [1]. Periprosthetic joint infections (PJIs), however, present a serious and challenging complication of both procedures. The annual incidence of PJI after primary TKA and THA is approximately 1 and 1%-2%, respectively [2,3]. As the number of joint arthroplasty procedures continues to rise, the annual hospital costs related to PJI in the hip and knee have been estimated to be $1.85 billion by 2030 [4]. In the last 2 decades, there have been significant advances in the diagnosis and management of PJI. Notably, several societies have developed guidelines to better standardize the diagnosis of PJI, including the 2011 Musculoskeletal Infection Society (MSIS) criteria [5], the 2018 International Consensus Meeting criteria [6], and the 2021 European Bone and Joint Infection Society (EBJIS) criteria [7]. With regard to management, increased focus on interdisciplinary management and selection of the optimal strategy based on microorganisms and antibiotic susceptibility have led to successful treatment rates above 90% for infected THA and TKA [[8], [9], [10], [11]]. Despite progress made, effectively managing this condition remains challenging, and microbiologic failure rates of up to 40% after one- or two-stage revision have been reported in the literature [[12], [13], [14], [15]]. Publications play an essential role in the dissemination of information, and highly cited articles often help guide and improve disciplinary development [16]. While the number of publications has increased substantially since the 2000s, a few landmark studies have been critical in establishing the research trends in the subject. Additionally, it still remains uncertain whether the rise in PJI publication volume correlates with an improvement in the level of evidence (LOE) of published articles. Therefore, our study sought to (1) analyze the characteristics of the 100 most cited publications about PJI from an orthopaedic standpoint, (2) provide an overview of their research highlights, and (3) assess whether there has been a change in the LOE throughout time. Material and methods Search strategy A first search of the Science Citation Index Expanded database of the Web of Science (WOS) Core Collection data was conducted on June 15, 2023, using the following search terms: "prosthetic joint infection" OR "periprosthetic joint infection" OR "PJI." This was followed by a second, expanded search of the PubMed, Embase, and WOS libraries on October 24, 2023. No language restrictions were imposed on our search. Article screening Our search resulted in a total of 5887, 7919, and 3393 studies from the PubMed, Embase, and WOS libraries, respectively (Fig. 1). After removing duplicates, the remaining 9644 studies were ranked based on the citation number. We established a cutoff value of greater than 100 citations, which excluded 9478 studies from our pool of potentially eligible studies. The chosen cutoff was arbitrarily selected in order to obtain a number slightly above 100 results, our target number of included studies. Titles and abstracts of the remaining studies were then independently screened by 2 reviewers (F.L. and J.D.) to confirm that the primary focus of the study was on PJI. In cases of disagreement between reviewers, the senior author was consulted, and a final decision was made through consensus. We did not exclude any articles based on a study’s methodology (eg, original article and systematic review). However, articles were excluded for the following reasons: focus on PJI from a nonorthopaedic standpoint; PJI was not the primary study focus; the study focused on orthopaedic infections broadly; and the study focused solely on shoulder PJI. After reviewing the 166 results obtained, we ultimately included the top 100 articles in our study. Flowchart of the identification of relevant articles. Data extraction Manuscripts of the 100 included articles were manually reviewed, and data were extracted into a standardized sheet. The following variables were extracted from each study: year and decade of publication, manuscript name, LOE, journal of publication, citation count, and type of study. LOE was evaluated following the guidelines established by the Journal of Bone and Joint Surgery [17]. The following study designs were established before the start of the study: (1) cohort study, (2) controlled trial, (3) review (narrative or systematic), (4) large database study, (5) definition of PJI study, (6) cost analysis study, and (7) other. We defined the following areas to cover in the Research highlights section: (1) epidemiology and cost analysis; (2) definition and diagnosis criteria; (3) laboratory tests; (4) prevention and risk factors for infection and/or recurrence; (5) treatment; and (6) complications. All 100 manuscripts were independently reviewed by 2 authors (M.R.G. and F.L.) to classify the main topic of each study and retrieve the key findings. Statistical analysis The correlation between LOE and year of publication was assessed using linear regression. The correlation coefficient (Pearson’s r) and coefficient of determination (R-squared) were calculated. A P-value ≤.05 was considered statistically significant. All analyses were performed using StataSE 14 (StataCorp, College Station, TX). Results Characteristics of included studies All articles included in our study were written in English (Supplementary Table 1). The total citation count ranged from 83 to 1131. The aggregated citation count of all studies was 19,558 and the median number of citations was 129.5. Median yearly citation count was 16. Articles included were published from 1995 to 2021. Most studies (82%) were published in the 2010s, followed by the 2000s (14%) and 2020s (3%). Only one study (1%) was published in the 1990s. The included articles were published in 12 journals. The largest share of included articles was published in Clinical Orthopaedics and Related Research (35%), followed by the Journal of Arthroplasty (23%) and the Journal of Bone and Joint Surgery (20%) (Table 1). The main study methodologies were retrospective cohorts (26%), large database studies (22%), and prospective cohorts (16%) (Table 2). Studies using large, national databases accounted for 22% of the included articles, and 15% were review articles (narrative or systematic). Studies establishing a definition or diagnosis criteria for PJI and those focusing on the cost of PJI had the highest median yearly citation (34 and 23, respectively) (Table 2). Table 1List of journals where included articles were published.JournalArticle count (n)CitationsIFaClinical Orthopaedics and Related Research3572074.2The Journal of Arthroplasty2354004.1The Journal of Bone and Joint Surgery2036035.3Bone & Joint Journal712804.6Acta Orthopaedica69034.0Journal of Orthopaedic Research33732.8Current Reviews in Musculoskeletal Medicine12104.8EFORT Open Reviews11554.8Journal of Knee Surgery11552.5Journal of the American Academy of Orthopaedic Surgeons1923.2Knee Surgery, Sports Traumatology, Arthroscopy1913.9BMC Musculoskeletal Disorders1892.3IF, impact factor.aImpact factor of the years 2022-2023. List of journals where included articles were published. IF, impact factor. Impact factor of the years 2022-2023. Table 2Citation metrics by type of study.Study typeNTotal citationsaPYearly citationsaPRetrospective cohort26132 (112, 155).6711 (7.9, 17).017Large database22116 (103, 164)15 (10, 25)Prospective cohort16120 (109, 204)18 (10, 28)Review (narrative or systematic)15155 (120, 223)18 (12, 23)Definition of PJI10173 (120, 531)34 (17, 71)Cost analysis5181 (120, 211)23 (16, 60)Controlled trial1116 (116, 116)12 (12, 12)Other5114 (107, 141)14 (9.7, 35)Bold values indicate P-value < .05.aValues displayed refer to the median and interquartile ranges between brackets. Citation metrics by type of study. Bold values indicate P-value < .05. Values displayed refer to the median and interquartile ranges between brackets. Highlights Epidemiology and cost analysis The 2 most cited studies on PJI focused on its incidence and associated costs. With regard to incidence, Pulido et al. reviewed 9245 patients from an arthroplasty registry and reported a PJI incidence of 0.7% [18]. The authors also reported a PJI incidence of 1.1% and 0.3% after TKA and THA, respectively. Additional studies on PJI incidence have reported an incidence rate of late PJI of 0.07% per prosthesis-year for TKA and THA [19], and a 5-year cumulative incidence of 0.64% for THA [20]. Kamath et al. quantified the burden of revision total joint arthroplasty for PJI and found that PJI was the first and third cause of revision TKA and THA, respectively [21]. From a cost perspective, Kurtz et al. reported that the annual cost of infected revisions in the United States increased from $320 million in 2001 to $566 million in 2009 and was projected to exceed $1.62 billion by 2020 [22]. Definition and diagnosis criteria With regard to diagnosis, Parvizi et al. demonstrated significant variability in sensitivity (54%-100%), specificity (39%-100%), and accuracy (53%-100%) using 6 different published sets of diagnostic criteria [23]. In this context, several diagnostic criteria developed by consensus emerged, including the 2018 International Consensus Meeting criteria [6], the 2011 MSIS criteria [5], and the 2021 EBJIS criteria [7]. While these criteria are applied worldwide to diagnose PJI, several modifications to them have been implemented, such as the addition of the leukocyte esterase test as a minor criterion to the 2011 MSIS criteria [24] and alpha-defensin to the 2021 EBJIS criteria [7]. Moreover, additional publications derived from consensus meetings have established research priorities on PJI diagnosis [25] and questioned whether these diagnosis criteria can be universally applied to both hip and knee PJI [26]. Laboratory tests The utility of laboratory tests, including inflammatory blood markers, has been highlighted by Berbari et al [27]. In this study, the authors reported that the diagnostic accuracy for PJI was best for interleukin-6, followed by C-reactive protein, erythrocyte sedimentation rate, and white blood cell count. Finding biomarkers for PJI have been a considerable research interest, with a study by Deirmengian et al. finding 100% sensitivity and specificity for 5 biomarkers (human α-defensin 1-3, neutrophil elastase 2, bactericidal/permeability-increasing protein, neutrophil gelatinase-associated lipocalin, and lactoferrin) [28]. Other studies have highlighted the accuracy of synovial fluid α-defensin, reporting a 100% sensitivity and specificity for the diagnosis of PJI [29]. Emphasis has also been placed on the leukocyte esterase strip test, underscoring its ease of use and good accuracy [[29], [30], [31], [32]]. A systematic review by Wyatt et al. reported a PJI pooled diagnostic sensitivity and specificity of leukocyte esterase of 81% and 97%, respectively [30]. Prevention and risk factors for infection and/or recurrence With the increase in PJI cases, studies have also focused on identifying risk factors for infection and treatment failure. In an analysis of the Medicare population, Kurtz et al. identified higher Charlson comorbidity index, male sex, subsidized premium, and longer operative time as risk factors for PJI after TKA [3]. In addition, Maoz et al. reported that a body mass index ≥40 kg/m2, operative time >115 minutes, nonsame-day surgery, and revision surgery were independent risk factors for PJI [33]. Other studies have focused on PJI microbiology, reporting that PJI caused by methicillin-resistant Staphylococcus aureus [34] or Gram-negative bacteria [35] is at higher risk of failure. Therefore, several studies have focused on PJI prevention strategies, highlighting the use of proper wound care, preoperative patient optimization, and modification of the operative room environment (e.g, laminar airflow) [36,37]. Treatment Development and standardization of an effective surgical strategy for PJI have been key objectives in the field of arthroplasty. In a cohort of 202 infected THA treated with two-stage revision, Berend et al. reported an 83% infection control rate among reimplanted patients [38]. Mortazavi et al. reported that 28% of patients with infected THA treated with two-stage revision underwent reoperation due to reinfection after reimplantation [39]. Additional studies reported infection control rates above 80% for infected TKA and THA, thus setting the stage for two-stage revision to be considered a standard for treating PJI [40,41]. With regard to alternative strategies, Haddad et al. reported similar infection recurrence rates between single-stage (0%) and two-stage (7%) revision arthroplasty in chronic knee PJI [42]. Finally, limited success has been reported with the use of debridement, antibiotics, and implant retention (DAIR) [[43], [44], [45]]. Deirmengian et al. found that only 35% of patients treated with DAIR successfully retained their components at the latest follow-up [45]. Other studies with higher sample sizes reported PJI treatment success rates of 44% [44] and 66% [43] for DAIR. Complications Despite advances in PJI diagnosis and management, this condition still poses a significant risk of complications, including death. Zmistowski et al. reported that mortality after revision for PJI was 3.7% at 90 days, 10.6% at one year, and 25.9% at 5 years, which was similar to the rate of mortality of colorectal, cervical, and head and neck cancer [46]. In agreement with these values, Gundtoft et al. reported that 8% of patients who underwent revision for PJI died within the year [47]. In a more recent systematic review, Natsuhara et al. found that 5-year mortality after revision for hip PJI was 21.1% [48]. While these numbers showcase the severity of PJI, Kurtz et al. reported that the risk of mortality after PJI has been decreasing between 2005 and 2015, likely due to advances in the field [49]. Level of evidence and publication year We identified six articles with level I evidence, 30 with level II evidence, 34 with level III evidence, 11 with level IV evidence, and 8 with level V evidence (Fig. 2a). Median total citation counts were 148 (interquartile range [IQR] 119-853) for level I studies, 193 (IQR 107-335) for level II studies, 114.5 (IQR 103-136) for level III studies, 138 (IQR 120-181) for level IV studies, and 141 (IQR 121.5-179.5) for level V studies. There was a trend toward higher median total citation counts in articles with level II evidence compared to other groups (P = .052) (Fig. 2b). (a) Bar chart displaying the frequency of articles by level of evidence. (b) Box and whiskers chart for total citations by level of evidence. On our regression analysis, there was no correlation between LOE and year of publication (Pearson’s r = 0.013, P = .61) (Fig. 3). This analysis indicated that a greater time period was not accompanied by an increase in the LOE. Plot displaying correlation between level of evidence and publication year. Discussion PJI, a severe complication after total joint arthroplasty, has seen a significant increase in publications over the last 2 decades. While some studies have examined the characteristics of highly cited papers in the PJI literature using bibliometrics [16,50], they lack practical insights for orthopaedic surgeons and focus solely on citation metrics. In contrast, our study aimed to outline the key findings of the top 100 most cited studies and evaluate whether the rise in peer-reviewed publications on PJI corresponded to enhanced study quality. Our analysis revealed that the majority of the top 100 most cited studies were cohort studies published primarily in 3 orthopaedic journals. Additionally, the most common topics of PJI publications encompassed the epidemiology, costs, definition and diagnosis, laboratory tests, prevention and risk factors for infection or recurrence, treatment, and complications of PJI. Most studies on the epidemiology and costs associated with PJI relied on large national databases [[20], [21], [22]]. While the use of large databases has been criticized due to their lack of granular data, our study showed that valuable insight on economic trends and epidemiologic metrics can be obtained. With regard to the definition and diagnosis of PJI, multiple sets of criteria by different societies were established [[5], [6], [7],23]; however, only one assessed the diagnostic performance of the newly established criteria in an external cohort of patients [6]. Laboratory testing mainly focused on inflammatory markers, with particular interest in synovial α-defensin and leukocyte esterase. Well-designed studies assessing the performance of these markers were widely cited due to their reported excellent diagnostic accuracy, accessibility, and ease of use [[28], [29], [30], [31]]. Interestingly, all evidence on current surgical treatment for PJI stemmed from retrospective or prospective studies with limited sample sizes [38,39,[42], [43], [44]]. Although two-stage exchange revision is often considered the gold standard in the treatment of PJI, none of the landmark studies have demonstrated superior treatment success rates compared to single-stage exchange arthroplasty. The research highlights of the main landmark studies in each of the six topics assessed can be found in Table 3. Table 3Research highlights of some of the landmark studies in periprosthetic joint infection.Research areaAuthorsResearch highlightsEpidemiology and cost analysisPulido et al. [18]0.7% PJI incidence after primary TJA; 1.1% and 0.3% PJI incidence after primary TKA and THA, respectively.Huotari et al. [19]1.2% cumulative incidence of PJI after primary TJA. Incidence of late PJI (>2 years postoperative) and very late PJI (>5 years postoperative) was 0.07% and 0.05% per prosthesis-year, respectively.Gundtoft et al. [20]One-year and 5-year cumulative incidence of PJI were 0.5% and 0.6%, respectively.Kamath et al. [21]PJI was the most common reason for revision TKA (25%) and the third most common for revision THA (15.4%).Kurtz et al. [22]Annual cost of infected revisions for PJI increased from $320 million to $566 million between 2001 and 2009 and was projected to exceed $1.62 billion by 2020.Definition and diagnosisParvizi et al. [23]Wide variability in sensitivity (54%-100%), specificity (39%-100%), and accuracy (53%-100%) using 6 sets of diagnostic criteria for PJI.Parvizi et al. [6]Introduction of the new ICM criteria and validation on external cohort. Sensitivity of 97.7% and specificity of 99.5% using the new criteria on validation cohort.Parvizi et al. [5]Introduction of a new definition for PJI by the MSIS workgroup.Mcnally et al. [7]Introduction of a new definition for PJI by the EBJIS.Laboratory testsBerbari et al. [27]The most accurate inflammatory markers for PJI diagnosis were interleukin-6 (diagnostic odds ratio [dOR] = 314.7), followed by CRP (dOR = 13.1), ESR (dOR = 7.2), and WBC (dOR = 4.4).Deirmengian et al. [28]Five biomarkers (α-defensin 1-3, neutrophil elastase 2, bactericidal/permeability-increasing protein, neutrophil gelatinase-associated lipocalin, and lactoferrin) correctly predicted the MSIS classification of all patients for the diagnosis of PJI.Deirmengian et al. [29]100% sensitivity and specificity for the diagnosis of PJI using synovial fluid α-defensin.Wyatt et al. [30]Systematic review: Pooled sensitivity and specificity of α-defensin for PJI of 100% and 96%, compared to 81% and 97% for leukocyte esterase.Wetters et al. [31]Sensitivity and specificity of 93.3% and 77% of leukocyte esterase in patients with PJI confirmed by cultures.Prevention and RF for infection and/or recurrenceKurtz et al. [3]CCI ≥5 (adjusted hazard ratio [aHR] = 2.16), operative time ≥210 minutes (aHR = 1.59), and Medicare premiums (aHR = 1.27) as risk factors for PJI.Maoz et al. [33]BMI ≥40 kg/m2 (odds ratio [OR] = 4.13), operating time >115 minutes (OR = 3.38), nonsame-day surgery (OR = 4.16), and revision surgery (OR = 4.13) as risk factors for PJI.Salgado et al. [34]Higher risk of treatment failure in PJI caused by methicillin-resistant S. aureus than in methicillin-susceptible S. aureus (hazard ratio = 9.2).Zmistowski et al. [35]Successful reimplantation after 2-stage revision in 52% of gram-negative, 51% of methicillin-resistant gram-positive, and 69% of methicillin-sensitive gram-positive PJI cases.TreatmentBerend et al. [38]7% of patients treated with 2-stage revision for hip PJI died before reimplantation. Among those who underwent re-implantation, 83% achieved infection control.Mortazavi et al. [39]28% of reimplantations required reoperation for reinfection. Culture-negative infection, methicillin-resistant organisms, and increased operative time as predictors of failure.Haddad et al. [42]0% (0/28) and 7% (5/74) infection recurrence in 28 patients treated with single-stage and two-stage revision for chronic TKA infection, respectively.Kuiper et al. [43]Treatment failure in 34% of patients treated with DAIR for hip or knee PJI.Azzam et al. [44]Treatment failure in 56% of patients treated with DAIR for hip or knee PJI.Deirmengian et al. [45]Implant retention in only 35% of patients initially treated with DAIR for acute knee PJI.ComplicationsZmistowski et al. [46]Significantly higher mortality in patients with PJI compared with those undergoing aseptic revision arthroplasty at 90 days (3.7% vs 0.8%), 1 year (10.6% vs 2.0%), 2 years (13.6% vs 3.9%), and 5 years (25.9% vs 12.9%).Gundtoft et al. [47]8% of patients who underwent revision for PJI died within a year. Adjusted relative mortality risk for patients with revision for PJI was 1.87 compared with revision for aseptic loosening.Natsuhara et al. [48]1-year and 5-year weighted mortality rates of 4.22% and 21.12% after total hip PJI.Kurtz et al. [49]Unadjusted 1-year and 5-year risk of PJI was 0.69% and 1.09% for THA and 0.74% and 1.38% for TKA, respectively. Risk of mortality after PJI decreased significantly by year for THA and TKA after adjustment.BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; DAIR, debridement, antibiotics, and implant retention; EBJIS, European Bone and Joint Infection Society; ESR, erythrocyte sedimentation rate; ICM, International Consensus Meeting; MSIS, musculoskeletal infection society; PJI, periprosthetic joint infection; RF, risk factor; THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty; WBC, white blood cell. Research highlights of some of the landmark studies in periprosthetic joint infection. BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; DAIR, debridement, antibiotics, and implant retention; EBJIS, European Bone and Joint Infection Society; ESR, erythrocyte sedimentation rate; ICM, International Consensus Meeting; MSIS, musculoskeletal infection society; PJI, periprosthetic joint infection; RF, risk factor; THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty; WBC, white blood cell. Despite the increase in PJI publication volume over time, we did not see a corresponding increase in LOE. This highlights the fact that, although the management of PJI has evolved, the evidence supporting these changes is mostly derived from LOE II or III studies. Since the incidence of PJI is low, conducting prospective PJI studies requires a large number of patients. While conducting randomized controlled trials (RCTs) in PJI remains challenging, a recent pragmatic, parallel group, open-label RCT from the UK demonstrated the feasibility of such a study [51]. In this study, the authors compared patient-reported outcomes after single-stage and two-stage revision for hip PJI and found no superiority in patient-reported outcome at 18 months in the single-stage group [51]. Our study had several limitations. First, we restricted our analysis to the top 100 most cited papers on PJI. This could introduce selection bias, potentially making our sample not representative of all PJI literature. Second, our analysis was limited to studies focusing on PJI from the orthopaedic standpoint. This strategy was decided prior to the beginning of the study to avoid having an overabundance of papers focusing on the microbiology or medical management of PJI, which are usually submitted to medical journals with different impact factors and may have higher citation counts. Third, our selection of articles relied solely on the total citation count. However, there are alternative metrics, such as the Research Interest score and Altmetric score, designed to gauge publication impact. We decided to base our analyses purely on citation count due to its long-standing track record, particularly within the orthopaedic literature. Conclusions We performed the first comprehensive analysis of the PJI literature from the orthopaedic perspective. Most studies included had LOE II or III. Furthermore, our study described the research highlights of the top 100 most cited papers and found that there was no correlation between publication time and LOE. This last finding highlights the challenges of performing high-quality RCT in PJI, as well as the reliance on LOE II or III studies to establish diagnosis and management guidelines for PJI. Conflicts of interest A. F. Chen receives royalties from Stryker; is a paid consultant for Adaptive Phage Therapeutics, Avanos, BICMD, Convatec, Ethicon, GLG, Guidepoint, Heraeus, IrriMax, Osteal Therapeutics, Peptilogics, Pfizer, Smith and Nephew, Stryker, and TrialSpark; owns stock or stock options in Hyalex, Irrimax, Osteal Therapeutics, Sonoran, and IlluminOss; receives research support from Adaptive Phage Therapeutics, Elute, Peptilogics, and Sectra; receives financial or material support from SLACK Incorporated, UpToDate, Taylor & Francis Group, and Journal of Bone and Joint Surgery; is an editorial or governing board member of Journal of Arthroplasty, Journal of Bone and Joint Infection, Journal of Bone and Joint Surgery, and Arthroplasty Today; and is a board/committee member of AAOS, AJRR, and AAHKS. All other authors declare no potential conflicts of interest. For full disclosure statements refer to https://doi.org/10.1016/j.artd.2024.101564. CRediT authorship contribution statement Marcos R. Gonzalez: Writing – original draft, Methodology, Formal analysis, Data curation. Jose I. Acosta: Writing – original draft, Data curation. Joshua Davis: Writing – original draft, Data curation. Felipe Larios: Writing – original draft, Data curation. Adam S. Olsen: Writing – review & editing, Conceptualization. Antonia F. Chen: Writing – review & editing, Supervision, Project administration, Conceptualization. Appendix Supplementary Table 1Summary of the 100 most cited studies.RankCitationTotal citationCitations since 20131Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012 Sep;27 (8 Suppl):61-5.e1.1131822Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008 Jul;466 (7):1710-5.895663Parvizi J, Jacovides C, Zmistowski B, Jung KA. Definition of periprosthetic joint infection: is there a consensus? Clin Orthop Relat Res. 2011 Nov;469 (11):3022-30.862244Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, Shohat N. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J Arthroplasty. 2018 May;33 (5):1309-1314.e2.853535Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on Periprosthetic Joint Infection. Bone Joint J. 2013 Nov;95-B (11):1450-2.617316Parvizi J, Gehrke T; International Consensus Group on Periprosthetic Joint Infection. Definition of periprosthetic joint infection. J Arthroplasty. 2014 Jul;29 (7):1331.531167Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res. 2010 Jan;468 (1):52-6.471358Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, Garvin KL, Mont MA, Wongworawat MD, Zalavras CG. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011 Nov;469 (11):2992-4.452339Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of 1-year mortality. J Bone Joint Surg Am. 2013 Dec 18;95 (24):2177-84.3883010Ong KL, Kurtz SM, Lau E, Bozic KJ, Berry DJ, Parvizi J. Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. J Arthroplasty. 2009 Sep;24 (6 Suppl):105-9.3541511Bozic KJ, Lau E, Kurtz S, Ong K, Rubash H, Vail TP, Berry DJ. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg Am. 2012 May 2;94 (9):794-800.3353212Berbari E, Mabry T, Tsaras G, Spangehl M, Erwin PJ, Murad MH, Steckelberg J, Osmon D. Inflammatory blood laboratory levels as markers of prosthetic joint infection: a systematic review and meta-analysis. J Bone Joint Surg Am. 2010 Sep 1;92 (11):2102-9.2892213Bozic KJ, Lau E, Kurtz S, Ong K, Berry DJ. Patient-related risk factors for postoperative mortality and periprosthetic joint infection in medicare patients undergoing TKA. Clin Orthop Relat Res. 2012 Jan;470 (1):130-7.2711614Deirmengian C, Kardos K, Kilmartin P, Cameron A, Schiller K, Parvizi J. Diagnosing periprosthetic joint infection: has the era of the biomarker arrived? Clin Orthop Relat Res. 2014 Nov;472 (11):3254-62.2663315Cui Q, Mihalko WM, Shields JS, Ries M, Saleh KJ. Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. J Bone Joint Surg Am. 2007 Apr;89 (4):871-82.265616Berend KR, Lombardi AV Jr, Morris MJ, Bergeson AG, Adams JB, Sneller MA. Two-stage treatment of hip periprosthetic joint infection is associated with a high rate of infection control but high mortality. Clin Orthop Relat Res. 2013 Feb;471 (2):510-8.2581017Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. Clin Orthop Relat Res. 2013 Jul;471 (7):2374-82.230918Mortazavi SM, Vegari D, Ho A, Zmistowski B, Parvizi J. Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure. Clin Orthop Relat Res. 2011 Nov;469 (11):3049-54.2261019Deirmengian C, Kardos K, Kilmartin P, Cameron A, Schiller K, Parvizi J. Combined measurement of synovial fluid α-Defensin and C-reactive protein levels: highly accurate for diagnosing periprosthetic joint infection. J Bone Joint Surg Am. 2014 Sep 3;96 (17):1439-45.2252620Gbejuade HO, Lovering AM, Webb JC. The role of microbial biofilms in prosthetic joint infections. Acta Orthop. 2015 Apr;86 (2):147-58.2233921Deirmengian C, Kardos K, Kilmartin P, Cameron A, Schiller K, Booth RE Jr, Parvizi J. The alpha-defensin test for periprosthetic joint infection outperforms the leukocyte esterase test strip. Clin Orthop Relat Res. 2015 Jan;473 (1):198-203.2121522Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty. 2010 Sep;25 (6 Suppl):103-7.2111523Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: current concepts and outlook. EFORT Open Rev. 2019 Jul 29;4 (7):482-494.2103324Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop Relat Res. 2003 Sep; (414):69-88.2073425Tsukayama DT, Goldberg VM, Kyle R. Diagnosis and management of infection after total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A Suppl 1:S75-80.205726Workgroup Convened by the Musculoskeletal Infection Society. New definition for periprosthetic joint infection. J Arthroplasty. 2011 Dec;26 (8):1136-8.2041227Dale H, Fenstad AM, Hallan G, Havelin LI, Furnes O, Overgaard S, Pedersen AB, Kärrholm J, Garellick G, Pulkkinen P, Eskelinen A, Mäkelä K, Engesæter LB. Increasing risk of prosthetic joint infection after total hip arthroplasty. Acta Orthop. 2012 Oct;83 (5):449-58.1952728Shahi A, Kheir MM, Tarabichi M, Hosseinzadeh HRS, Tan TL, Parvizi J. Serum D-Dimer Test Is Promising for the Diagnosis of Periprosthetic Joint Infection and Timing of Reimplantation. J Bone Joint Surg Am. 2017 Sep 6;99 (17):1419-1427.1952229Parvizi J, Jacovides C, Antoci V, Ghanem E. Diagnosis of periprosthetic joint infection: the utility of a simple yet unappreciated enzyme. J Bone Joint Surg Am. 2011 Dec 21;93 (24):2242-8.1911230Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res. 2007 Aug;461:48-53.182831Kamath AF, Ong KL, Lau E, Chan V, Vail TP, Rubash HE, Berry DJ, Bozic KJ. Quantifying the Burden of Revision Total Joint Arthroplasty for Periprosthetic Infection. J Arthroplasty. 2015 Sep;30 (9):1492-7.1811632Brown NM, Cipriano CA, Moric M, Sporer SM, Della Valle CJ. Dilute betadine lavage before closure for the prevention of acute postoperative deep periprosthetic joint infection. J Arthroplasty. 2012 Jan;27 (1):27-30.178933Tarabichi M, Shohat N, Goswami K, Alvand A, Silibovsky R, Belden K, Parvizi J. Diagnosis of Periprosthetic Joint Infection: The Potential of Next-Generation Sequencing. J Bone Joint Surg Am. 2018 Jan 17;100 (2):147-154.1753334Kuiper JW, Vos SJ, Saouti R, Vergroesen DA, Graat HC, Debets-Ossenkopp YJ, Peters EJ, Nolte PA. Prosthetic joint-associated infections treated with DAIR (debridement, antibiotics, irrigation, and retention): analysis of risk factors and local antibiotic carriers in 91 patients. Acta Orthop. 2013 Aug;84 (4):380-6.1651135Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are We Winning or Losing the Battle With Periprosthetic Joint Infection: Trends in Periprosthetic Joint Infection and Mortality Risk for the Medicare Population. J Arthroplasty. 2018 Oct;33 (10):3238-3245.1641036Koh CK, Zeng I, Ravi S, Zhu M, Vince KG, Young SW. Periprosthetic Joint Infection Is the Main Cause of Failure for Modern Knee Arthroplasty: An Analysis of 11,134 Knees. Clin Orthop Relat Res. 2017 Sep;475 (9):2194-2201.1621337Azzam KA, Seeley M, Ghanem E, Austin MS, Purtill JJ, Parvizi J. Irrigation and debridement in the management of prosthetic joint infection: traditional indications revisited. J Arthroplasty. 2010 Oct;25 (7):1022-7.155938Della Valle C, Parvizi J, Bauer TW, Dicesare PE, Evans RP, Segreti J, Spangehl M, Watters WC 3rd, Keith M, Turkelson CM, Wies JL, Sluka P, Hitchcock K; American Academy of Orthopaedic Surgeons. Diagnosis of periprosthetic joint infections of the hip and knee. J Am Acad Orthop Surg. 2010 Dec;18 (12):760-70.1551039Aggarwal VK, Bakhshi H, Ecker NU, Parvizi J, Gehrke T, Kendoff D. Organism profile in periprosthetic joint infection: pathogens differ at 2 arthroplasty infection referral centers in Europe and in the United States. J Knee Surg. 2014 Oct;27 (5):399-406.1551440Parvizi J, Azzam K, Ghanem E, Austin MS, Rothman RH. Periprosthetic infection due to resistant staphylococci: serious problems on the horizon. Clin Orthop Relat Res. 2009 Jul;467 (7):1732-9.153641Gomez MM, Tan TL, Manrique J, Deirmengian GK, Parvizi J. The Fate of Spacers in the Treatment of Periprosthetic Joint Infection. J Bone Joint Surg Am. 2015 Sep 16;97 (18):1495-502.153442Bingham J, Clarke H, Spangehl M, Schwartz A, Beauchamp C, Goldberg B. The alpha defensin-1 biomarker assay can be used to evaluate the potentially infected total joint arthroplasty. Clin Orthop Relat Res. 2014 Dec;472 (12):4006-9.1431143McNally M, Sousa R, Wouthuyzen-Bakker M, Chen AF, Soriano A, Vogely HC, Clauss M, Higuera CA, Trebše R. The EBJIS definition of periprosthetic joint infection. Bone Joint J. 2021 Jan;103-B (1):18-25.1411444Schwarz EM, Parvizi J, Gehrke T, Aiyer A, Battenberg A, Brown SA, Callaghan JJ, Citak M, Egol K, Garrigues GE, Ghert M, Goswami K, Green A, Hammound S, Kates SL, McLaren AC, Mont MA, Namdari S, Obremskey WT, O'Toole R, Raikin S, Restrepo C, Ricciardi B, Saeed K, Sanchez-Sotelo J, Shohat N, Tan T, Thirukumaran CP, Winters B. 2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. J Orthop Res. 2019 May;37 (5):997-1006.1411845Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J. Infection control rate of irrigation and débridement for periprosthetic joint infection. Clin Orthop Relat Res. 2011 Nov;469 (11):3043-8.138546Meehan JP, Danielsen B, Kim SH, Jamali AA, White RH. Younger age is associated with a higher risk of early periprosthetic joint infection and aseptic mechanical failure after total knee arthroplasty. J Bone Joint Surg Am. 2014 Apr 2;96 (7):529-35.136847Lee YS, Koo KH, Kim HJ, Tian S, Kim TY, Maltenfort MG, Chen AF. Synovial Fluid Biomarkers for the Diagnosis of Periprosthetic Joint Infection: A Systematic Review and Meta-Analysis. J Bone Joint Surg Am. 2017 Dec 20;99 (24):2077-2084.1362148Mortazavi SM, Schwartzenberger J, Austin MS, Purtill JJ, Parvizi J. Revision total knee arthroplasty infection: incidence and predictors. Clin Orthop Relat Res. 2010 Aug;468 (8):2052-9.1351049Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty. 2011 Sep;26 (6 Suppl):104-8.131650Parvizi J, Erkocak OF, Della Valle CJ. Culture-negative periprosthetic joint infection. J Bone Joint Surg Am. 2014 Mar 5;96 (5):430-6.1311951Haddad FS, Sukeik M, Alazzawi S. Is single-stage revision according to a strict protocol effective in treatment of chronic knee arthroplasty infections? Clin Orthop Relat Res. 2015 Jan;473 (1):8-14.128552Wyatt MC, Beswick AD, Kunutsor SK, Wilson MJ, Whitehouse MR, Blom AW. The Alpha-Defensin Immunoassay and Leukocyte Esterase Colorimetric Strip Test for the Diagnosis of Periprosthetic Infection: A Systematic Review and Meta-Analysis. J Bone Joint Surg Am. 2016 Jun 15;98 (12):992-1000.1271653Malekzadeh D, Osmon DR, Lahr BD, Hanssen AD, Berbari EF. Prior use of antimicrobial therapy is a risk factor for culture-negative prosthetic joint infection. Clin Orthop Relat Res. 2010 Aug;468 (8):2039-45.125454Maoz G, Phillips M, Bosco J, Slover J, Stachel A, Inneh I, Iorio R. The Otto Aufranc Award: Modifiable vs nonmodifiable risk factors for infection after hip arthroplasty. Clin Orthop Relat Res. 2015 Feb;473 (2):453-9.1231255Shohat N, Bauer T, Buttaro M, Budhiparama N, Cashman J, Della Valle CJ, Drago L, Gehrke T, Marcelino Gomes LS, Goswami K, Hailer NP, Han SB, Higuera CA, Inaba Y, Jenny JY, Kjaersgaard-Andersen P, Lee M, Llinás A, Malizos K, Mont MA, Jones RM, Parvizi J, Peel T, Rivero-Boschert S, Segreti J, Soriano A, Sousa R, Spangehl M, Tan TL, Tikhilov R, Tuncay I, Winkler H, Witso E, Wouthuyzen-Bakker M, Young S, Zhang X, Zhou Y, Zimmerli W. Hip and Knee Section, What is the Definition of a Periprosthetic Joint Infection (PJI) of the Knee and the Hip? Can the Same Criteria be Used for Both Joints?: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty. 2019 Feb;34 (2S):S325-S327.123856Font-Vizcarra L, García S, Martínez-Pastor JC, Sierra JM, Soriano A. Blood culture flasks for culturing synovial fluid in prosthetic joint infections. Clin Orthop Relat Res. 2010 Aug;468 (8):2238-43.123957Bonanzinga T, Zahar A, Dütsch M, Lausmann C, Kendoff D, Gehrke T. How Reliable Is the Alpha-defensin Immunoassay Test for Diagnosing Periprosthetic Joint Infection? A Prospective Study. Clin Orthop Relat Res. 2017 Feb;475 (2):408-415.121758Deirmengian C, Greenbaum J, Lotke PA, Booth RE Jr, Lonner JH. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J Arthroplasty. 2003 Oct;18 (7 Suppl 1):22-6.121359Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, Sculco PK. Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States. J Arthroplasty. 2021 May;36 (5):1484-1489.e3.1201960Zmistowski B, Della Valle C, Bauer TW, Malizos KN, Alavi A, Bedair H, Booth RE, Choong P, Deirmengian C, Ehrlich GD, Gambir A, Huang R, Kissin Y, Kobayashi H, Kobayashi N, Krenn V, Lorenzo D, Marston SB, Meermans G, Perez J, Ploegmakers JJ, Rosenberg A, C Simpfendorfer, Thomas P, Tohtz S, Villafuerte JA, Wahl P, Wagenaar FC, Witzo E. Diagnosis of periprosthetic joint infection. J Orthop Res. 2014 Jan;32 Suppl 1:S98-107.1201061Gehrke T, Alijanipour P, Parvizi J. The management of an infected total knee arthroplasty. Bone Joint J. 2015 Oct;97-B (10 Suppl A):20-9.1201562Renz N, Yermak K, Perka C, Trampuz A. Alpha Defensin Lateral Flow Test for Diagnosis of Periprosthetic Joint Infection: Not a Screening but a Confirmatory Test. J Bone Joint Surg Am. 2018 May 2;100 (9):742-750.119663Cordero-Ampuero J, de Dios M. What are the risk factors for infection in hemiarthroplasties and total hip arthroplasties? Clin Orthop Relat Res. 2010 Dec;468 (12):3268-77.1181964Ghanem E, Azzam K, Seeley M, Joshi A, Parvizi J. Staged revision for knee arthroplasty infection: what is the role of serologic tests before reimplantation? Clin Orthop Relat Res. 2009 Jul;467 (7):1699-705.116265Marculescu CE, Cantey JR. Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res. 2008 Jun;466 (6):1397-404.116766Gollwitzer H, Dombrowski Y, Prodinger PM, Peric M, Summer B, Hapfelmeier A, Saldamli B, Pankow F, von Eisenhart-Rothe R, Imhoff AB, Schauber J, Thomas P, Burgkart R, Banke IJ. Antimicrobial peptides and proinflammatory cytokines in periprosthetic joint infection. J Bone Joint Surg Am. 2013 Apr 3;95 (7):644-51.1162867Buller LT, Sabry FY, Easton RW, Klika AK, Barsoum WK. The preoperative prediction of success following irrigation and debridement with polyethylene exchange for hip and knee prosthetic joint infections. J Arthroplasty. 2012 Jun;27 (6):857-64.e1-4.115368Ragni MV, Crossett LS, Herndon JH. Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. J Arthroplasty. 1995 Dec;10 (6):716-21.114169Huotari K, Peltola M, Jämsen E. The incidence of late prosthetic joint infections: a registry-based study of 112,708 primary hip and knee replacements. Acta Orthop. 2015 Jun;86 (3):321-5.112770Holinka J, Bauer L, Hirschl AM, Graninger W, Windhager R, Presterl E. Sonication cultures of explanted components as an add-on test to routinely conducted microbiological diagnostics improve pathogen detection. J Orthop Res. 2011 Apr;29 (4):617-22.1121171Frangiamore SJ, Gajewski ND, Saleh A, Farias-Kovac M, Barsoum WK, Higuera CA. α-Defensin Accuracy to Diagnose Periprosthetic Joint Infection-Best Available Test? J Arthroplasty. 2016 Feb;31 (2):456-60.112772Wetters NG, Berend KR, Lombardi AV, Morris MJ, Tucker TL, Della Valle CJ. Leukocyte esterase reagent strips for the rapid diagnosis of periprosthetic joint infection. J Arthroplasty. 2012 Sep;27 (8 Suppl):8-11.111673Tsaras G, Maduka-Ezeh A, Inwards CY, Mabry T, Erwin PJ, Murad MH, Montori VM, West CP, Osmon DR, Berbari EF. Utility of intraoperative frozen section histopathology in the diagnosis of periprosthetic joint infection: a systematic review and meta-analysis. J Bone Joint Surg Am. 2012 Sep 19;94 (18):1700-11.1101074Cipriano CA, Brown NM, Michael AM, Moric M, Sporer SM, Della Valle CJ. Serum and synovial fluid analysis for diagnosing chronic periprosthetic infection in patients with inflammatory arthritis. J Bone Joint Surg Am. 2012 Apr 4;94 (7):594-600.109775Lai K, Bohm ER, Burnell C, Hedden DR. Presence of medical comorbidities in patients with infected primary hip or knee arthroplasties. J Arthroplasty. 2007 Aug;22 (5):651-6.109276Gundtoft PH, Pedersen AB, Varnum C, Overgaard S. Increased Mortality After Prosthetic Joint Infection in Primary THA. Clin Orthop Relat Res. 2017 Nov;475 (11):2623-2631.108277Panousis K, Grigoris P, Butcher I, Rana B, Reilly JH, Hamblen DL. Poor predictive value of broad-range PCR for the detection of arthroplasty infection in 92 cases. Acta Orthop. 2005 Jun;76 (3):341-6.108778Adeli B, Parvizi J. Strategies for the prevention of periprosthetic joint infection. J Bone Joint Surg Br. 2012 Nov;94 (11 Suppl A):42-6.1071179Chrastil J, Anderson MB, Stevens V, Anand R, Peters CL, Pelt CE. Is Hemoglobin A1c or Perioperative Hyperglycemia Predictive of Periprosthetic Joint Infection or Death Following Primary Total Joint Arthroplasty? J Arthroplasty. 2015 Jul;30 (7):1197-202.107680Jacovides CL, Kreft R, Adeli B, Hozack B, Ehrlich GD, Parvizi J. Successful identification of pathogens by polymerase chain reaction (PCR)-based electron spray ionization time-of-flight mass spectrometry (ESI-TOF-MS) in culture-negative periprosthetic joint infection. J Bone Joint Surg Am. 2012 Dec 19;94 (24):2247-54.1071381Parvizi J, Shohat N, Gehrke T. Prevention of periprosthetic joint infection: new guidelines. Bone Joint J. 2017 Apr;99-B (4 Supple B):3-10.1042182Bozic KJ, Ong K, Lau E, Berry DJ, Vail TP, Kurtz SM, Rubash HE. Estimating risk in Medicare patients with THA: an electronic risk calculator for periprosthetic joint infection and mortality. Clin Orthop Relat Res. 2013 Feb;471 (2):574-83.1031283Greenky M, Gandhi K, Pulido L, Restrepo C, Parvizi J. Preoperative anemia in total joint arthroplasty: is it associated with periprosthetic joint infection? Clin Orthop Relat Res. 2012 Oct;470 (10):2695-701.103584Aggarwal VK, Higuera C, Deirmengian G, Parvizi J, Austin MS. Swab cultures are not as effective as tissue cultures for diagnosis of periprosthetic joint infection. Clin Orthop Relat Res. 2013 Oct;471 (10):3196-203.103885Parvizi J, Ghanem E, Sharkey P, Aggarwal A, Burnett RS, Barrack RL. Diagnosis of infected total knee: findings of a multicenter database. Clin Orthop Relat Res. 2008 Nov;466 (11):2628-33.103586Gundtoft PH, Overgaard S, Schønheyder HC, Møller JK, Kjærsgaard-Andersen P, Pedersen AB. The "true" incidence of surgically treated deep prosthetic joint infection after 32,896 primary total hip arthroplasties: a prospective cohort study. Acta Orthop. 2015 Jun;86 (3):326-34.100287Healy WL, Iorio R, Clair AJ, Pellegrini VD, Della Valle CJ, Berend KR. Complications of Total Hip Arthroplasty: Standardized List, Definitions, and Stratification Developed by The Hip Society. Clin Orthop Relat Res. 2016 Feb;474 (2):357-64.991488Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br. 2005 Feb;87 (2):249-56.97589Boddapati V, Fu MC, Mayman DJ, Su EP, Sculco PK, McLawhorn AS. Revision Total Knee Arthroplasty for Periprosthetic Joint Infection Is Associated With Increased Postoperative Morbidity and Mortality Relative to Noninfectious Revisions. J Arthroplasty. 2018 Feb;33 (2):521-526.95590Kurd MF, Ghanem E, Steinbrecher J, Parvizi J. Two-stage exchange knee arthroplasty: does resistance of the infecting organism influence the outcome? Clin Orthop Relat Res. 2010 Aug;468 (8):2060-6.95291Sigmund IK, Holinka J, Gamper J, Staats K, Böhler C, Kubista B, Windhager R. Qualitative α-defensin test (Synovasure) for the diagnosis of periprosthetic infection in revision total joint arthroplasty. Bone Joint J. 2017 Jan;99-B (1):66-72.94992Odum SM, Fehring TK, Lombardi AV, Zmistowski BM, Brown NM, Luna JT, Fehring KA, Hansen EN; Periprosthetic Infection Consortium. Irrigation and debridement for periprosthetic infections: does the organism matter? J Arthroplasty. 2011 Sep;26 (6 Suppl):114-893593Klug A, Gramlich Y, Rudert M, Drees P, Hoffmann R, Weißenberger M, Kutzner KP. The projected volume of primary and revision total knee arthroplasty will place an immense burden on future health care systems over the next 30 years. Knee Surg Sports Traumatol Arthrosc. 2021 Oct;29 (10):3287-3298.92794Goswami K, Parvizi J, Maxwell Courtney P. Current Recommendations for the Diagnosis of Acute and Chronic PJI for Hip and Knee-Cell Counts, Alpha-Defensin, Leukocyte Esterase, Next-generation Sequencing. Curr Rev Musculoskelet Med. 2018 Sep;11 (3):428-438.911095Li R, Shao HY, Hao LB, Yu BZ, Qu PF, Zhou YX, Chen JY. Plasma Fibrinogen Exhibits Better Performance Than Plasma D-Dimer in the Diagnosis of Periprosthetic Joint Infection: A Multicenter Retrospective Study. J Bone Joint Surg Am. 2019 Apr 3;101 (7):613-619.911196Choi HR, von Knoch F, Zurakowski D, Nelson SB, Malchau H. Can implant retention be recommended for treatment of infected TKA? Clin Orthop Relat Res. 2011 Apr;469 (4):961-9.90297Masters JP, Smith NA, Foguet P, Reed M, Parsons H, Sprowson AP. A systematic review of the evidence for single stage and 2 stage revision of infected knee replacement. BMC Musculoskelet Disord. 2013 Jul 29;14:222.892698Mahmud T, Lyons MC, Naudie DD, Macdonald SJ, McCalden RW. Assessing the gold standard: a review of 253 two-stage revisions for infected TKA. Clin Orthop Relat Res. 2012 Oct;470 (10):2730-6.87199Natsuhara KM, Shelton TJ, Meehan JP, Lum ZC. Mortality During Total Hip Periprosthetic Joint Infection. J Arthroplasty. 2019 Jul;34 (7S):S337-S342.879100Parisi TJ, Konopka JF, Bedair HS. What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis. Clin Orthop Relat Res. 2017 Jul;475 (7):1891-1900.835 Summary of the 100 most cited studies. Supplementary data Conflict of Interest Statement for Olsen Conflict of Interest Statement for Chen Conflict of Interest Statement for Larios Conflict of Interest Statement for Acosta Conflict of Interest Statement for Davis Conflict of Interest Statement for Gonzalez References Associated Data Supplementary Materials Conflict of Interest Statement for Olsen Conflict of Interest Statement for Chen Conflict of Interest Statement for Larios Conflict of Interest Statement for Acosta Conflict of Interest Statement for Davis Conflict of Interest Statement for Gonzalez